Focused On-demand Library for Ninein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8N4C6

UPID:

NIN_HUMAN

Alternative names:

Glycogen synthase kinase 3 beta-interacting protein

Alternative UPACC:

Q8N4C6; A6NDB8; B7WPA3; C9JSB6; C9JSG2; C9JXL2; Q5BKU3; Q6P0P6; Q9BWU6; Q9C012; Q9C013; Q9C014; Q9H5I6; Q9HAT7; Q9HBY5; Q9HCK7; Q9UH61

Background:

Ninein, also known as Glycogen synthase kinase 3 beta-interacting protein, plays a crucial role in centrosomal and microtubule organization. It is essential for the positioning and anchorage of microtubule minus-ends in epithelial cells, centrosome maturation, and microtubule nucleation. Ninein recruits the gamma-tubulin ring complex to the centrosome, facilitating microtubule nucleation without affecting their nucleation or elongation but suppresses their release.

Therapeutic significance:

Ninein's mutation is linked to Seckel syndrome 7, a rare autosomal recessive disorder characterized by dwarfism, low birth weight, severe microcephaly, and intellectual disability. Understanding the role of Ninein could open doors to potential therapeutic strategies for treating Seckel syndrome 7 and improving patient outcomes.